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Obesity is an ever growing pandemic and a prevalent problem among men of
reproductive age that can both cause and exacerbate male-factor infertility by means
of endocrine abnormalities, associated comorbidities, and direct effects on the precision
and throughput of spermatogenesis. Robust epidemiologic, clinical, genetic, epigenetic,
and preclinical data support these findings. Clinical studies on the impact of medically
induced weight loss on serum testosterone concentrations and spermatogenesis is
promising but may show differential and unsustainable results. In contrast, literature
has demonstrated that weight loss after bariatric surgery is correlated with an increase
in serum testosterone concentrations that is superior than that obtained with only
lifestyle modifications, supporting a further metabolic benefit from surgery that may be
specific to the male reproductive system. The data on sperm and semen parameters
is controversial to date. Emerging evidence in the burgeoning field of genetics and
epigenetics has demonstrated that paternal obesity can affect offspring metabolic and
reproductive phenotypes bymeans of epigenetic reprogramming of spermatogonial stem
cells. Understanding the impact of this reprogramming is critical to a comprehensive view
of the impact of obesity on subsequent generations. Furthermore, conveying the potential
impact of these lifestyle changes on future progeny can serve as a powerful tool for obese
men to modify their behavior. Healthcare professionals treating male infertility and obesity
need to adapt their practice to assimilate these new findings to better counsel men about
the importance of paternal preconception health and the impact of novel non-medical
therapeutic interventions. Herein, we summarize the pathophysiology of obesity on the
male reproductive system and emerging evidence regarding the potential role of bariatric
surgery as treatment of male obesity-associated gonadal dysfunction.
Keywords: obesity, male reproductive system, male obesity related hypogonadism, bariatric surgery, metabolic
surgery, male subfertility, oligospermia, erectile dysfunction
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INTRODUCTION
Obesity is a multifactorial global pandemic, which affects
virtually every system in the body and can have significant bio-
psycho-social impacts on the patients. It is increasingly becoming
a significant health issue, which now affects all age groups and is
seen in the developed and developing world (1). In the year 2016,
the World Health Organization (WHO) data showed that 39% of
the world’s population is overweight and 13% are obese (1).
Obesity results from complex interactions between metabolic,
genetic, environmental, nutritional, and psychosocial factors.
Excess body weight has been established as a clear risk for
increased morbidity and mortality and is a known risk factor for
several serious physical health conditions such as hypertension,
type II diabetes mellitus (T2DM), dyslipidemia, cerebrovascular,
and cardiovascular illness (2). In addition we now know
that obesity also impacts both male and female sexual and
reproductive function (2). Throughout history and pervading
many civilizations the penis in an erect state has been a powerful
symbol of male fertility, virility, and dominance. Therefore,
the inability to achieve and/or maintain an erection can have
profound negative physical and psychological effects on the
patient as an individual and indirectly on the partner (3).
AETIOPATHOGENESIS OF MALE OBESITY
RELATED HYPOGONADISM
Testosterone Deficiency
The male reproductive system is a multilevel complex
physiological system that is controlled by various feedback
mechanisms and signaling molecules, which are all in a
delicate balance. Hypogonadism is defined as decreased or
absent gonadal function and in males is characterized by
reduced testosterone levels (4). There exists an expectation that
testosterone levels will naturally decline with age and can lead
to or strongly contribute to hypogonadism (5). Obesity and in
particular, visceral adipose tissue expansion, represents a strong
risk factor for the development of male hypogonadism and this
state is referred to as male obesity secondary hypogonadism
(MOSH) (6). The effects of MOSH will manifest themselves as
testosterone deficiency, erectile dysfunction, changes in sperm,
and semen parameters and overall sexual dysfunction (6). The
current scientific literature shows established links between
obesity and secondary hypogonadism where one cross sectional
study has demonstrated an 8.7-fold increase in risk of secondary
hypogonadism in patients with a BMI >30 kg/m2 (7).
Furthermore, men with a BMI of 35–40 kg/m2 can have up
to 50% less free and total testosterone when compared to age
matched peers with a normal BMI (8). There is overwhelming
undisputed evidence of the link between obesity and male sexual
and reproductive dysfunction however the exact mechanisms for
this remains to be elucidated (7–9).
The Cohen hypothesis was the first suggested link between
testosterone and obesity in the literature (10). This is based on
the observation that testosterone and obesity have a circular
relationship in which obesity acts as a strong independent
risk factor to testosterone deficiency (10). Similarly suboptimal
testosterone levels can in their own right exacerbate obesity
leading to a vicious cycle, which can only be broken with
substantial reduction in body mass (10). Figure 1 shows this
relationship and highlights other contributing causes.
Testosterone is known to be a hormone that has potent
metabolic effects and it is now accepted that testosterone
levels and subsequent effects are closely related to body mass
although the exact mechanism remain to be elucidated (11). In
suboptimal levels, testosterone will facilitate the differentiation of
pluripotent stem cells into adipocytes, which will cause increased
aromatization of testosterone into oestradiol (11). This will
act via negative feedback mechanism to the hypothalamic –
pituitary axis (HPA) to suppress further gonadal stimulation and
testosterone release (11).
In addition to those mechanisms in Cohen’s hypothesis,
testosterone deficiency is known to play indirect metabolic
roles preventing physiological compensatory mechanisms (11).
This is explored in the hypogonadal—obesity—adipocytokine
hypothesis, which expands this idea further (11). Testosterone
is known to enhance the activity of lipoprotein lipase enzyme,
which leads to a rise in triglyceride uptake into adipocytes (11).
Furthermore, larger numbers of adipocytes lead to increases
in insulin resistance, production of pro-inflammatory cytokines
tumor necrosis factor-a. interleukin-1 and interleukin-6 (TNF-
α, IL-1, and IL-6), and increases in leptin and oestradiol levels
(11, 12).
Leptin is a hormone produced by adipocytes, and acts to
regulate energy balance ensuring reduced fat storage (13). It
FIGURE 1 | The metabolic and reproductive effects of testosterone in relation
to obesity. Factors related to obesity, such as OSA and reduced SHGB
contribute to Testosterone deficiency. Reduced Osteocalcin output from
Osteoblasts is also newly associated with contributing to testosterone
deficiency. Testosterone deficiency increases activity of Lipoprotein Lipase and
therefore triglyceride uptake which increases visceral adipose tissues. This
further exacerbates htperinsulinemia and testosterone deficiency through the
activities of Aromatase enzyme. Visceral adipose tissue increases production
of cytokines and inflammatory mediators leading to a pro-inflammatory and
contribute to hypothalamic-pituitary suppression leading to further
testosterone deficiency.
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also has other roles and acts at the hypothalamic- pituitary level
to influence the reproductive system in both male and female
patients (13). In normal conditions, Leptin potentiates the release
of testosterone, by acting at the hypothalamic level, stimulating
neurons to release gonadotrophin releasing hormone (GnRH),
and subsequently luteinizing hormone (LH) from the pituitary
gland (13). However, in obesity these neurons become resistant
to the actions of Leptin (11, 13). In addition, receptors for Leptin
have been found in testicular tissue and studies have shown that
Leptin can directly inhibit gonadotrophic actions on Leydig cells
thus further exacerbating testosterone deficiency and therefore
obesity (11, 13).
The initial signals that activate the hypothalamic- pituitary-
gonadal axis originate in the arcuate nucleus and periventricular
nucleus of the hypothalamus (14). These neurons release
neuropeptide Kisspeptin, which in turn stimulates the release
of GnRH (14). Excess levels of oestradiol and pro-inflammatory
cytokines act at the hypothalamic level to inhibit the neuronal
release of Kisspeptin, which will lead to a profound reduction in
GnRH signals leading to a sustained state of hypogonadotropic
hypogonadism (12, 15).
Another hypothesis for male hypogonadism in obesity is
the Gelding theory. Currently, within the scientific literature
there has been more evidence supporting this theory as
at least contributing to testosterone deficiency. Within the
gastrointestinal system there exists on average 1.5 kg (100 trillion)
of bacteria (16, 17). This tends to be largely gram-negative
bacteria, which produce a pro-inflammatory lipopolysaccharide
and endotoxin (16, 17). Under normal circumstances these
proinflammatory substances are confined to the gastrointestinal
tract (16, 17). However, a highly calorific and fatty diet has
been shown to contribute to breakdown in the intestinal mucosa
leading to passage of bacterial endotoxins into the general
circulation, which further contributes to a pro-inflammatory
state (16, 17). Exposure to lipopolysaccharide from the general
circulation is hypothesized to cause impaired testicular function
thereby contributing to testosterone deficiency. The exact
mechanism of how this occurs remains unclear (16, 17).
Sex Hormone Binding Globulin (SHBG) is a glycoprotein
produced by the liver. In the circulation, ∼98% of testosterone
is bound to albumin and SHBG (18, 19). Suboptimal SHBG
levels can exacerbate testosterone deficiency through pro-
inflammatory effects and increased deposition of lipids within
macrophages and adipocytes. This will exacerbate the existing
inflammatory state of obesity and propagate further weight gain
(18). In addition, it is now accepted that suboptimal levels
of SHBG and testosterone significantly contribute to insulin
resistance and therefore a pre-diabetic state. The MRFIT and
the Massachusetts Male Aging Study followed up 176 and 1,156
patients over 5 and 7–10 years, respectively (20, 21). Both showed
results that are consistent with the wider literature, which is that
low levels of testosterone and SHBG were strongly associated
with the development of diabetes (20, 21). In obese patients
there exists a state of hyperinsulinemia due to reduced insulin
sensitivity in peripheral tissues (6). This leads to high levels of
insulin, which have been shown to contribute to firstly central
hypogonadism through the modulation of GnRH and therefore
gonadotrophin output and secondly to peripheral hypogonadism
through direct actions on Leydig cells (6, 22, 23).
Testosterone levels are also influenced by Obstructive Sleep
Apnea (OSA), which is a common condition and often co-exists
with obesity and excess body weight (24, 25). The underlying
pathophysiological mechanism of OSA involves partial or
complete upper airway obstruction, which results in intermittent
hypoxia, sleep fragmentation, reduced deep, and rapid eye
movement (REM) sleep and daytime somnolence (24, 25) OSA
has been associated with pituitary-gonadal dysfunction in male
patients, which is manifested as suboptimal testosterone levels,
erectile dysfunction, and reduced libido (24, 25). Suboptimal
testosterone levels found in OSA are due to reduced quality and
quantity of sleep, which in turn worsens both obesity and OSA
(24, 25).
Erectile Dysfunction
Testosterone deficiency also leads to difficulties in achieving and
maintaining an erection. Healthy erectile function is dependent
on interactions of erectile tissue, central, and peripheral
nervous system, several endocrine, and psychological factors (3).
Sexual stimulation results in activation of non-adrenergic, non-
cholinergic, and parasympathetic cholinergic nerve fibers leading
to the release of nitric oxide and acetylcholine, respectively (3).
This will lead to increased cyclic guanosine monophosphate
(GMP) and reduced intracellular calcium levels thus facilitating
the relaxation of smooth muscles and vasodilatation causing
increased blood flow to corpus cavernosum causing veno-
occlusion of the subtunical venules (3). Disturbances in one or
more of these mechanisms can contribute or lead to erectile
dysfunction (3, 26).
Excess body weight has been strongly linked to erectile
dysfunction and in fact current research has suggested high
BMI as a significant risk factor for erectile dysfunction (27,
28). Obesity leads to a pro-inflammatory physiological state,
which favors widespread arteriolar endothelial dysfunction and
impaired activity of nitric oxide. In addition, it also leads to
increased insulin and leptin resistance, which can exacerbate
T2DM and resultant peripheral neuropathies (29). Obesity is
also known to cause both central and peripheral hypogonadism
and testosterone deficiency thus further exacerbating erectile
dysfunction (29).
Current literature has shown that patients with a raised BMI
have a 30% increased risk of erectile dysfunction than those
of a normal BMI, and 96.5% of obese patients with metabolic
syndrome report erectile dysfunction (30, 31). A multivariate
analysis conducted by Bacon et al. showed an increased risk
of erectile dysfunction at 19 and 33% in men with a BMI of
25–26.9 and 27–29.9kg/m2, respectively (32, 33). The risk of
erectile dysfunction is further compounded in patients with
obesity due to the presence of other co-morbid conditions such as
cardiovascular dysfunction and T2DM (29, 34). A meta-analysis
investigating the prevalence of erectile dysfunction in T2DM
showed that 52.5% of diabetic patients report erectile dysfunction
giving prevalence odds of approximately 3.5 times more than
healthy individuals (34).
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Erectile dysfunction is essentially reflective of underlying
vascular disease in those patients with obesity and some
researchers have suggested that the presence of erectile
dysfunction can be used as a prompt for further assessment of
cardiovascular system (28).
Sperm and Semen Parameters
Obesity has a clear negative effect on male reproductive and
sexual function, however the effect of obesity on sperm and
semen parameters remains ambiguous. It is wholly accepted
that obesity increases oxidative stress through a prolonged and
sustained pro-inflammatory state, which is hypothesized to cause
oxidative damage to the sperm. This is thought to lead to
decreased motility, increased DNA damage, reduced acrosomal
reactions, and therefore lower successful outcomes following
in vitro Fertilization (IVF) (6, 35).
Some studies have suggested that elevated BMI results
in a detrimental effect on sperm morphology, motility, and
concentration however others have found no association (36–
38). Belloc et al. investigated 10,665 semen samples and found
that in morbidly obese patients (BMI >40 kg/m2) there was
reduced semen volume, concentration, total sperm count, and
reducedmotility (39). There were also significant increases found
in azoospermia and cryptozoospermia from 1.9 and 4.7% to 9.1
and 15.2%, respectively (39). Similarly Sermondade et al. carried
out a systemic review investigating the effect of BMI on sperm
count. They found that compared to men of normal BMI, those
in the obese or morbidly obese categories had an odds ratio of
1.28 (1.06–1.55) and 2.04 (1.59–2.62) for oligozospermia and
azoospermia, respectively (40). In contrast, a cross sectional study
by Rufus et al. carried out a comparison of semen quality in
206 men of varying BMI (41). The overall outcome of the study
was that elevated BMI did not have a significant effect on semen
quality (41).
It is clear that there is no consensus in the current literature
regarding the effects of obesity and excess body weight on sperm
and semen parameters. Further research is required into this area
so that we may better understand the effects of obesity on male
reproduction. This will inevitably allow the provision of more
targeted and therefore more effective treatment for reproductive
issues in male patients with obesity.
Effects of Paternal Obesity Through Future
Generations
Intragenerational inheritance occurs when induced epigenetic
changes in the gametes are passed on to the subsequent
generation (42). This epigenetic inheritance can lead to changes
to the phenotype of the offspring and beyond generations.
Transmission of epigenetic signatures for the paternal gamete,
includes any sperm epigenetic signatures altered throughout
a man’s life (or even that were induced in utero) from the
father to the child only and termed intergenerational.
Whereas, the inheritance of an altered epigenetic state
beyond immediate offspring is termed transgenerational
inheritance. According to epidemiological evidence, many
types of environmental challenges imposed on the parent,
such as hunger, specific diets, toxins, and trauma, have been
found to influence the development of the offspring (43).
Paternal age, subfertility, smoking, obesity, and exposure to
a range of environmental influences, including air pollution,
radiofrequency electromagnetic radiation and others, have also
been implicated (44). The Dutch famine study showed that severe
caloric restriction in parents during wartime starvation in World
War II, resulted in significant cardiometabolic abnormalities in
the post-utero life of their offsprings (45).
Obesity has been shown to directly drive transgenerational
effects in successive generations. Preclinical studies with
the use of animal models have found altered metabolic
processing in offspring sired by obese fathers (46). Further
studies using murine models have shown similar patterns of
offspringmetabolic perturbations but have also identified specific
epigenetic alterations in the sperm (47). In humans, an intriguing
recent study found alterations in DNAmethylation at the insulin-
like growth factor 2 gene in newborns sired by obese fathers (48).
Taken together, data from experimental studies strongly suggest
that obesity can affect sperm function, embryogenesis, and even
offspring health; though, the same results have not been clearly
demonstrated in humans (49, 50).
Donkin et al., demonstrated that the expression level of
specificmiRNAs, and small nuclear RNA (snRNA) fragments was
altered in the spermatozoa of obese men. They speculated that
this altered expression coordinately modulated the expression of
genes involved in behavior and food intake and could participate
in predisposing the offspring to obesity (50).
MANAGEMENT OF MALE OBESITY
RELATED HYPOGONADISM
Non-surgical Interventions
Current management of obesity entails access to specialized
secondary and tertiary care services that allow patients to
engage with a multidisciplinary team to aid weight loss and
maintenance. Lifestyle modifications such as caloric deficit diets
and increased physical activity are the mainstay of non-surgical
therapies. Recently, treatment with a Glucagon Like Peptide−1
(GLP-1) receptor agonist has shown beneficial effects with
regards to weight loss but have also shown increased levels of
gonadotrophins and subsequent increases in testosterone (50).
Several studies have demonstrated benefits with regards to
improvement and recovery in the male reproductive system
following significant and sustained weight loss. The European
Male Aging Study (EMAS) has shown that changes in total
body weight of ≥15% are correlated to changes in testosterone
whereby gaining weight reduces testosterone levels and vice versa
(51). Similarly the Massachusetts Male Aging Study established
that a 4–5 kg/m2 increase in BMI significantly contributes to a
reduction in total testosterone level comparable to 10 years of
aging (52). Hakonsen et al. also demonstrated similar results in
a pilot cohort study of 43 men who were enrolled in a residential
weight loss program. This study showed an average weight loss of
15%, which correlated to improvement in hormonal profile and
an increase in total sperm count and semen volume (53). Mir
et al. also showed that weight loss leads to significant reduction
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in DNA fragmentation index and therefore improved sperm
morphology (37).
In a cross-sectional prospective cohort study, Bacon et al.
demonstrate that physical activity is associated with 30%
decreased risk of erectile dysfunction (31). Further studies have
explored the relationship of weight to erectile function and have
used the International Index of Erectile Function (IIEF) score.
One such study demonstrated that lifestyle measures can cause a
reduction in BMI from 36.9 to 31.2 kg/m2 and improvement in
IIEF score from 13.9 to 17, respectively (54).
Bariatric Surgery: Hormonal and Metabolic
Effects
Intense and sustained lifestyle modifications can show adequate
weight loss of up to 10% at 1 year with up to 5.3% maintained
at 8 years (55). However, a subset of obese and morbidly obese
patients will require surgical interventions in the form of bariatric
surgery (55). Eligibility for surgical intervention in the treatment
of obesity is globally variable; however, it is generally accepted
that bariatric surgery could be an appropriate option for patients
with a BMI >40 kg/m2 or those with a BMI of 35–40 kg/m2
with co-morbid conditions (55). There are different surgeries
available however all seem to show favorable outcomes. In a
systematic review by O’Brien et al., patients achieved 71, 60,
and 49% excess weight loss with a biliopancreatic diversion
with duodenal switch (BPD/DS), laparoscopic Roux en Y gastric
bypass (RYGB) and laparoscopic adjustable gastric band (LAGB),
respectively. (56, 57). Such drastic and sustained weight loss will
have profound effects on alleviation of obesity and associated co-
morbid conditions. Table 1 shows relevant studies investigating
the effect of bariatric surgery on hormonal and metabolic profile,
erectile dysfunction, and semen and sperm parameters.
In addition to significant and sustained weight loss,
several studies have also demonstrated improvement in total
testosterone, SHBG levels, insulin resistance, and several other
metabolic parameters (63, 72). Interestingly, the improvements
in these parameters are not procedure specific (63, 72). Extensive
and sustained weight loss leading to improvement in MOSH
has consistently been reported in the literature. In a systematic
review and meta-analysis of 45 articles, MOSH was present in
64% of patients preoperatively with resolution seen in 87% of
patients post-operatively (73). Similarly, Pellitero et al. carried
out an observational study of 33 men undergoing bariatric
surgery and showed that 1 year post-operatively there was
significant excess weight loss observed at 18.8% with an increase
in total and free testosterone, SHBG and FSH and decrease in
estradiol and prolactin (63).
Further studies have also demonstrated that decreases in
visceral adipose tissue leads to increases in free testosterone
and these effects are thought to be long lasting (6, 74). Visceral
adipose tissue is known to contain higher levels of aromatase
enzyme thereby contributing to excess conversion of testosterone
to estradiol (6, 74). Therefore, it would make sense that reduction
in visceral adipose tissue could disturb this mechanism and lead
to a rise in testosterone levels and therefore overall improvement
in MOSH (6).
It is now accepted that obesity and excess body weight creates
a pro-inflammatory physiological state that directly causes or
exacerbates several health conditions including MOSH. Studies
have shown favorable outcomes in terms of reduction in pro-
inflammatory mediators following bariatric surgery. This is seen
in a study of 20 morbidly obese subjects undergoing adjustable
gastric banding. One year post operatively they had significant
reduction in BMI from 41.6 to 30.8 kg/m2 and high sensitivity
C Reactive Protein (hs-CRP) from 1.33 to 0.4 mg/dl, respectively
(62). These results were replicated in a study of 47 patients (BMI
>40 kg/m2), and post operatively, subjects were found to have
lost an average of 33% of their body weight, which was correlated
with a reduction of hs-CRP from 0.83 to 0.18 mg/dl (56, 75).
Bariatric surgery clearly shows immediate and
sustained reduction in BMI and therefore improvement
in pathophysiological factors causing or contributing to
hypogonadism. Pham et al. have also shown that these effects do
persist long term (71). They carried out a randomized controlled
trial of 32 male obese patients assigned to medical therapy or
surgical treatment (76). Surgical patients showed an increase
of 47.4% in free testosterone compared to medical patients at a
2.2% increase only. The increases in testosterone also correlated
to decreased high sensitivity CRP, leptin, and overall BMI (76).
Experimental evidence has suggested potential links between
the skeletal and reproductive system. Osteoblasts produce a
hormone called Osteocalcin, which acts directly on the Leydig
cells in the testes to produce testosterone (77). Samavat et al.
have shown that reduction in BMI leads to increased levels
in Osteocalcin, which also correlates to an increased level of
testosterone (78). It is widely accepted that testosterone is a
hormone, which exerts significant metabolic effects in both
direct and indirect manners (78). This is clearly an area that is
promising however requires further research to elucidate exact
effects and how dependent they may be on other risk factors such
as age or other comorbidities.
Bariatric Surgery: Erectile Dysfunction
There is agreement in the literature regarding the detrimental
effects of obesity and excess body weight on erectile function.
The impact of erectile dysfunction on the individual patient but
also in a partnership is profound and can lead to significant
negative effects on quality of life. This effect is ameliorated
with reduction in BMI and improvements can be seen in
biological and psychological factors contributing to reproductive
and sexual function (58, 65). In a systematic review and meta-
analysis assessing erectile function in patients with obesity pre-
and post-operatively showed a 4.10 increase in the IIEF score
demonstrating statistical significance (79). Furthermore, a study
of 97 patients with obesity undergoing bariatric surgery showed
improvement in sexual drive, erectile and ejaculatory function,
and sexual satisfaction post operatively. These effects were
directly correlated to percentage of excess body weight lost (64).
In a prospective study by Arolfo et al. data was collected pre-
and 12 months post-operatively on 44 male patients. Patients had
significant improvement in IIEF 12 months after surgery (59).
Improvement in sexual function and specifically erectile
function is clearly seen with bariatric surgery and correlated to
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TABLE 1 | Effects of bariatric surgery on hormonal and metabolic profile, erectile dysfunction, semen and sperm parameters.
Level of
evidence
References Sample Size Intervention Outcome
Level Ib Samavat et al. (58) 103 Gastric bypass Post operative time point review: 9 months
Weight loss achieved: Mean −36.2 ± 20.24 kg
Outcome: significant increase in free and total testosterone, OCN and
SHBG; decrease in Oestradiol
Level Ib Arolfo et al. (59) 44 Roux-en-y gastric bypass;
Sleeve gastrectomy
Post operative time point review: 9 months
Weight loss achieved: Mean-39.75 ± 24 kg
Outcome: Significant increase in total testosterone, SHBG and IIEF
score; decrease in HbA1c, insulin, triglycerides, HDL cholesterol, and
CRP
Level Ib Legro et al. (60) 6 Roux-en-y gastric bypass Post operative time point review: 1, 3, 6 months
Weight loss achieved: Mean −55 ± 30 kg
Outcome: improvement in testosterone level
Level Ib Reis et al. (61) 20 Lifestyle modifications, Gastric
bypass
Post operative time point review: 4 and 24 months
Weight loss achieved: inaccessible
Outcome: improvement in total and free testosterone and FSH and
reduced prolactin levels
Level IIb Liu et al. (62) 45 Roux-en-y gastric bypass Post operative time point review:
Weight loss achieved: inaccessible
Outcome: increase in total testosterone with reduced visceral fat
Level IIIb Calderon et al. (63) 35 Gastric bypass; Sleeve
gastrectomy; Gastric Banding
Post operative time point review: 6 months or more (not specified)
Weight loss achieved: −51.0 ± 20.7 kg for RYGB group and −31.1 ±
17.6 kg for the restrictive surgery group
Outcome: increase in total testosterone and SHBG; decrease in fasting
glucose and insulin
Level Ia Glina et al. (64) 7 articles Bariatric surgery—Review article Outcome: improvement in IIEF score
Level IIb Dallal et al. (65) 97 Gastric bypass Post—operative time point review: 19 months
Weight loss achieved: Mean 53 ± 29 kg
Outcome: improvement in sexual drive, erectile function, ejaculatory
function, and sexual satisfaction
Level IIb Kun et al. (66) 39 Roux-en-y gastric bypass Post operative time point review: 12 months
Weight loss achieved: Unspecified
Mean pre-op BMI: 41.2 ± 8.5 kg/m2 and post-op 32.1 ± 7.3 kg/m2
Outcome: improvement in cavernosal thickness and vasculopathy,
endothelial function scores, and IIEF
Level Ia Wei et al. (67) 6 articles Gastric bypass—Review article Outcome: increase in semen volume; no changes in semen
concentration or motility
Level IIa Carette et al. (68) 46 Gastric bypass; Sleeve
gastrectomy
Post operative time point review: 6 and 12 months
Weight loss achieved: inaccessible
Outcome: increase sperm count likely due to resolution of
hypogonadism and DNA fragmentation
Level IIb Samavat et al. (69) 31 Roux-en-y gastric bypass;
Medical management
Post operative time point review: 0 and 6 months
Weight loss achieved: Mean −34.7 ± 16.7 kg
Outcome: improvement in total sperm motility and number; Statistically
significant increase in semen volume. Reduced Il- 8 levels and sperm
DNA fragmentation
Level IV Sermondade et al. (70) 3 Roux-en-y gastric bypass;
Sleeve gastrectomy
Post operative time point review: not specified
Weight loss achieved: Unspecified
Case 1: −32.3 kg/m2
Case 2: −23.1 kg/m2
Case 3: −11.1 kg/m2
Outcome: severe worsening of parameters in 2 patients; reversibility
seen in 1 patient 2 years post-operatively
Levels of evidence based on Oxford Center for Evidence Based Medicine criteria (71).
OCN, Osteocalcin; SHBG, Serum Hormone Binding Globulin; IIEF, International Index of Erectile Function; HDL, High Density Lipoproteins; CRP, C-Reactive Protein; FSH, Follicle
Stimulating Hormone.
improvements in hormonal profile. However, the positive effects
seen on erectile function are thought to be due to more than
just an improvement in hormonal and metabolic profiles. We
know that erectile dysfunction in part results from issues with the
integrity of blood vessels in penis. In fact, some researchers have
also suggested that erectile dysfunction could be a manifestation
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of vascular disease and endothelial dysfunction (59). This theory
was reinforced in a retrospective cohort study by Kun et al. in
which 39 obese men were investigated and 46.2 and 53.8% had
cavernosal vasculopathy and carotid vasculopathy, respectively
(76). This reduced post bariatric surgery to 15.4 and 23.1%
and subsequently led to an improvement in IIEF from 17.3 to
23.8 (80).
In reality, improvement in erectile function and in fact
reversal of erectile dysfunction is likely due to a drastic and
maintained reduction in excess weight leading to a more
favorable hormonal and metabolic profile. Further amelioration
of other co-morbidities and risk factors such as endothelial
dysfunction clearly significantly contributes to better outcomes.
Bariatric Surgery: Sperm and Semen
Parameters
The effects of bariatric surgery on hormonal profiles and erectile
function in male patients with obesity are clearly favorable.
However, the impact on semen and sperm parameters remains
inconsistent within the current literature. Samavat et al. assessed
morbidly obese patients 6 months after laparoscopic RYGB and
found improvement in overall semen volume and viability (66).
In addition, they found a decrease in serum Il-8 levels and sperm
DNA fragmentation (66).
Similarly, a systematic review and meta-analysis of 6 articles
showed that patients who had undergone gastric bypass surgery
had an increase in semen volume (69).
Conversely, Lee et al. carried out a systematic review and
meta-analysis of 28 cohort studies in which sperm parameters
were reported in only three of those articles and showed no
statistically significant difference pre- and post- bariatric surgery
(67). Furthermore the BARIASPERM study, assessing 46 male
patients with no prior history of infertility, showed that sperm
count at 6 and 12 months post operatively was significantly
reduced (81). Patients underwent either a gastric bypass surgery
or a sleeve gastrectomy with both showing reduced total sperm
count at−41.1 million and−91.1 million, respectively (81).
The reasons underlying these negative effects are likely
multifactorial involving different underlying pathophysiological
mechanisms. Rapid and sizeable excess body weight loss can lead
to nutritional deficiencies such as iron, calcium, and vitamins.
This occurs in varying severity depending on the surgical
procedure and can have a negative effect on spermatogenesis
leading to worsening parameters (68). In addition, weight loss
of such proportion can lead to release of liposoluble toxic
substances that can cause alterations in spermatogenesis (68).
A case series by Sermondade et al. analyzed three patients
and found worsening sperm parameters in all three patients
however in one case this effect was reversed after 24 months
(68). This further supports the theory above suggesting that
over time stabilization of nutritional status and reduction in
toxic metabolites may have eventually led to improved sperm
parameters (58). It is clear that there is no consensus currently in
the scientific literature on the effects of bariatric surgery on sperm
and semen parameters. Further studies with larger populations
are required to elucidate exact effects and suggest underlying
pathophysiological mechanisms.
CONCLUSION
Obesity has become a global pandemic affecting both developed
and developing nations. It has significant health consequences
on the individual including issues relating to sexual and
reproductive health. Bariatric surgery, as a metabolic treatment
for obesity, is clearly very effective in terms of rapid and sustained
reductions in BMI leading to restoration of reproductive
and metabolic hormonal profile. Significant weight loss also
alleviates the pro-inflammatory state that is associated with
obesity and other co-morbid conditions and helps restore
endothelial integrity thereby reducing erectile dysfunction and
other cardiovascular risk burden. Bariatric surgery produces
successful and encouraging outcomes in terms of the patient’s
overall health and well-being but more specifically seems to
ameliorate hypogonadism and sexual dysfunction.
There remain several unanswered questions in relation to the
effects of bariatric surgery on male fertility. The evidence of the
effects of surgical interventions on sperm and semen parameters
remains conflicting with no consensus reached in the current
literature. It is clear from this review that most studies included
are small and largely involve retrospective data analysis which is
a clear area of improvement in future research and a limitation of
this manuscript. Experimental medicine studies interrogating the
elusive pathophysiology of obesity and male reproductive system
can be invaluable in the optimisation of current and development
of future tailored metabolic interventions to treat male obesity
related reproductive dysfunction.
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